Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
23.7 USD | +5.97% | +23.66% | -12.68% |
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- With an enterprise value anticipated at 4.4 times the sales for the current fiscal year, the company turns out to be overvalued.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-12.68% | 2.74B | C | ||
-25.87% | 9.87B | A- | ||
-11.15% | 2.24B | - | B- | |
-19.81% | 1.63B | C+ | ||
+60.15% | 1.39B | B- | ||
+28.75% | 772M | C- | ||
-1.31% | 760M | C+ | ||
-24.49% | 516M | C- | ||
+5.37% | 310M | - | - | |
+12.46% | 219M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GH Stock
- Ratings Guardant Health, Inc.